In:
Turkish Journal of Diabetes and Obesity, Bulent Evcevit University, Vol. 6, No. 2 ( 2022-08-31), p. 137-142
Abstract:
Aim: In real life, we aimed to evaluate the effect of new generation insulin glargine u-300 on fasting blood glucose, HbA1c, LDL and triglyceride levels. Material and Methods: This is a retrocspective cohort study. We retrospectively reviewed patients who applied to the Endocrinology and metabolism outpatient clinic of Eskişehir Osmangazi University in 2019, whose old generation basal insulin was replaced with glargine u-300 and whose antilipidemic treatment was not changed. We compared fasting blood glucose(mg/dl), HbA1c(%), LDL(mg/ dl) and triglyceride(mg/dl) values at baseline and after 3 months. We also evaluated these data by separating them into genders. Shapiro– Wilk normality test was performed for continuous variables. Wilcoxon Signed Ranks test was performed for non-normally distributed variables. Results: Data concerning 109 patients were analysed. The fasting blood glucose average and median value decreased in control after starting glarjin u-300. However, it was not statistically different (p=0.06). The HbA1c control value (8.8%) decreased statistically significantly compared to the baseline value (9.61%) (p
Type of Medium:
Online Resource
ISSN:
2587-0335
Uniform Title:
Effects of Glargine u300 on Low-Density Lipoprotein (LDL), Triglyceride(TG) and Blood Glucose Levels: Real-Life Outcomes
DOI:
10.25048/tudod.1092781
Language:
Turkish
,
English
Publisher:
Bulent Evcevit University
Publication Date:
2022
Bookmarklink